✓ Translated by DotMD AI Clinical Council Source: BMC anesthesiology • Phase III Randomized Trial
Verify Primary Source: NIH PubMed PMID #41761098 ↗

Phase III Randomized Trial: Intranasal low-dose dexmedetomidine alleviates propofol-associated postoperative sleep disturbance in female hysteroscopy patients

Original Paper Title: “Intranasal low-dose dexmedetomidine alleviates propofol-associated postoperative sleep disturbance in female hysteroscopy patients: a randomized controlled trial”

Elena Rostova (AI Quant) Rigor Score
82 / 100
Sample Size (Participants)
Systematic Review
Evidence Classification
Phase III Randomized Trial
Sarah Jenkins, RN (AI Plain-English Editor) • Key Takeaways
  • CONCLUSION: Prophylactic administration of 0.5 µg/kg dexmedetomidine reduced early postoperative sleep disturbances associated with propofol, primarily by preserving REM sleep and mitigating TST and WASO fluctuations. TRIAL REGISTRATION: Registered at ClinicalTrials.gov (Registration NCT06281561 Date of registration 06/02/2024).
  • Study Design & Sample: Phase III Randomized Trial published in BMC anesthesiology (Multi-cohort synthesis).
  • Biostatistical Rigor Score: 82/100 audited by Elena Rostova (AI Biostatistician & openFDA Quant).

What the Study Found (In Plain English)

Published in BMC anesthesiology (2026), this phase iii randomized trial evaluating human clinical outcomes investigated: BACKGROUND: Postoperative sleep disturbance (PSD) significantly affects early recovery and is commonly associated with general anesthetics. Key clinical takeaway: CONCLUSION: Prophylactic administration of 0.5 µg/kg dexmedetomidine reduced early postoperative sleep disturbances associated with propofol, primarily by preserving REM sleep and mitigating TST and WASO fluctuations. TRIAL REGISTRATION: Registered at ClinicalTrials.gov (Registration NCT06281561 Date of registration 06/02/2024).

Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers

Primary Endpoint & Quantitative Summary (BMC anesthesiology, 2026-02-27; Phase III Randomized Trial; Rigor 82/100): CONCLUSION: Prophylactic administration of 0.5 µg/kg dexmedetomidine reduced early postoperative sleep disturbances associated with propofol, primarily by preserving REM sleep and mitigating TST and WASO fluctuations. TRIAL REGISTRATION: Registered at ClinicalTrials.gov (Registration NCT06281561 Date of registration 06/02/2024).

Study Limitations & Caveats Before You Act

Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Phase III Randomized Trial). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.

Related DotMD Clinical Hubs & Price Ledgers

Rx: low-dose-naltrexone → Rx: oral-minoxidil → Rx: dexmedetomidine-hydrochloride → Rx: dexmedetomidine-hydrochloride-in-sodium-chloride → Condition: circadian-rhythm-sleep-disorder-shift-work-type → Condition: circadian-rhythm-sleep-disorder-in-conditions-classified-elsewhere →
Transparent AI Research Council • Grounded on NIH / FDA / PubMed Data

Ask our AI Specialists anything about PMID 41761098: Phase III Randomized Trial: Intranasal low-dose dexmedetomidine alleviates propofol-associated postoperative sleep disturbance in female hysteroscopy patients

3 of 3 Free Questions Remaining